**S4 Table . Normalization of serum ALT**

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | ETV group | TDF group | *P* |
| Normalization of serum ALT |  | 0.32\* |
|  Baseline  | 0/108  | 0/37  |  |
|  Month 3 | 53/101 (52.5%) | 20/36 (55.6%) |  |
|  Month 6 | 73/102 (71.6%) | 25/35 (71.4%) |  |
|  Month 12 | 82/102 (80.4%) | 26/35 (74.3%) |  |
|  Month 18 | 79/95 (83.2%) | 12/14 (85.7%) |  |

\**P* value using generalized estimating equation analysis after adjustment for HBV DNA level, the presence of HBeAg, and history of CVS during prior treatment.

ETV, entecavir; TDF, tenofovir disoproxil fumarate; ALT, alanine aminotransferase; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; CVS, complete virological suppression.